Table 3.
Estimated three-year overall survival rate, and three-year cumulative incidence of local failure, and distant failure according to variables included in the multivariate analysis final models.
| Overall Survival | Local Failure | Distant Failure | |
|---|---|---|---|
| Factor | Three-year rate (95% CI) | Three-year cumulative incidence (95% CI) | Three-year cumulative incidence (95% CI) |
| Age at diagnosis | NA1 | − | − |
| KPS | |||
| <80 | 14.5% (8.3–22.3%) | − | − |
| ≥80 | 37.3% (30.9–43.7%) | − | − |
| History of smoking | |||
| Former | − | 46.6% (39.9–53.3%) | − |
| Current | − | 50.6% (40.3–60.9%) | − |
| Never | − | 69.5% (47.6–91.4%) | − |
| T stage | |||
| T1 | 43.9% (32.2–55.0%) | − | − |
| T2 | 29.6% (21.3–38.3%) | − | − |
| T3 | 22.5% (13.7–32.6%) | − | − |
| T4 | 17.9% (8.9–29.4%) | − | − |
| Tx | 54.5% (22.9–78.0%) | − | − |
| Histology | |||
| Squamous cell | − | − | 37.7% (28.9–46.5%) |
| Adenocarconima | − | − | 60.3% (52.7–67.9%)) |
| Other/NOS | − | − | 51.1% (36.4–65.7%) |
| Histologic grade | |||
| Moderate | − | − | 61.5% (45.3–77.6%) |
| Poor | − | − | 52.5% (44.0–61.0%) |
| Unknown | − | − | 46.3% (38.2–54.3%) |
| Radiation dose, Gy | |||
| <60.0 | 29.1% (17.8–41.3%) | 58.2% (44.8–71.6%) | − |
| 60.0 to 66.0 | 30.5% (23.4–37.9%) | 52.3% (44.4–60.1%) | − |
| >66.0 | 30.2 (21.8–38.9%) | 40.3% (31.2–49.4%)) | − |
| GTV | NA1 | − | NA1 |
| Primary tumor radiographic size | − | NA1 | − |
| Treatment modality | |||
| Definitive RT only | 14.2% (7.9–22.1%) | − | − |
| Sequential CRT | 36.9%(30.6–43.2%) | − | − |
NA: not available, KPS: Karnofsky performance status, NOS: not otherwise specified, Gy: Gray, GTV: primary and nodal gross tumor volume, RT: radiotherapy, CRT: chemoradiation.
*
Based on log transformed data.
1
Estimate is not available for a continuous variable.